Of the 975 participants who presented with moderate/severe anaemia (Hb < 10 g/dL) either on or after the day primaquine was administered (day 0, 2, or 3) and within 7 days of the first dose of ACT administration, 72.6% (708) had at least one subsequent measurement. This evidence concerns the gene GSTM1 and anemia (phenotype).